EternaTear is developing a next-generation artificial tear formulation that utilizes a novel mechanism to enhance retention on the eye's surface, providing longer-lasting relief for dry eye symptoms. This product addresses the limitations of current over-the-counter eye drops, which require frequent reapplication and fail to treat the underlying causes of dry eye.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dry eye is caused by the tear film's inability to protect the eye's surface, leading to itching, burning, and pain. Current over-the-counter eye drops provide only temporary relief, require frequent reapplication (up to 6-12 times daily), and fail to address the underlying causes of dry eye. Untreated dry eye can result in permanent corneal damage and a significantly reduced quality of life.
Solution
EternaTear is developing a next-generation artificial tear formulation designed to provide longer-lasting relief for dry eye symptoms. The formulation utilizes a novel mechanism that enhances retention on the eye's surface, reducing the need for frequent reapplication. By mimicking natural tears more closely, EternaTear aims to provide more effective and sustained relief compared to existing over-the-counter options. This approach targets both the symptoms and potentially some of the underlying issues associated with dry eye, offering a more comprehensive solution.
Target Audience
The primary target audience includes individuals suffering from dry eye symptoms who seek longer-lasting and more effective relief than current over-the-counter eye drops provide.
Features
- Novel mechanism for enhanced retention on the eye's surface
- Designed to reduce the frequency of application compared to current eye drops
- Aims to provide longer-lasting relief from dry eye symptoms
- Formulation intended to closely mimic natural tears